Health · Full coverage
New Drug Ensitrelvir Shows Promise in Preventing COVID-19 Infection After Exposure
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
100% center
Center 2
First reported by Mako · Jul 9, 2026
What happened
A new study shows that the antiviral drug Ensitrelvir can prevent COVID-19 infection in people exposed to the virus, reducing infection risk by over two-thirds. Approved in Japan and recently by the FDA in the U.S., the drug disrupts viral replication and delays symptom onset, offering a new preventive option beyond vaccines.
- 01Ensitrelvir reduces COVID-19 infection risk by over two-thirds after exposure.
- 02The drug delays symptom onset in those who still become infected.
- 03Clinical trials involved 1,000 participants across five countries from 2023 to 2024.
- 04Ensitrelvir inhibits a viral enzyme essential for virus replication.
- 05FDA approved Ensitrelvir for COVID-19 prevention in June 2026.
- 06No significant side effects were reported in the study.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
FDA Approves Revtorpyk to Cut Advanced Breast Cancer Progression Risk by 76%Jul 15, 2026FDA Approves New Daily Pill for Lowering Bad Cholesterol with Israeli Clinical Trial ParticipationJul 17, 2026AI-Developed Psoriasis Drug Outperforms Leading Treatment in Phase 3 TrialJun 30, 2026Teva Reports Positive Phase 1b Results for Vitiligo Antibody, Plans Phase 2b in 2026Jul 7, 2026Roche Launches Pioneering Trial to Prevent Alzheimer’s Before Symptoms AppearJul 15, 2026FDA Approves First Dual-Action Drug for IgA Nephropathy Kidney DiseaseJul 9, 2026
